Abstract
The Gram-negative opportunistic bacterium Acinetobacter baumannii is a significant cause of hospital-borne infections worldwide. Alarmingly, the rapid development of antimicrobial resistance coupled with the remarkable ability of isolates to persist on surfaces for extended periods of time has led to infiltration of A. baumannii into our healthcare environments. A major virulence determinant of A. baumannii is the presence of a capsule that surrounds the bacterial surface. This capsule is comprised of tightly packed repeating polysaccharide units which forms a barrier around the bacterial cell wall, providing protection from environmental pressures including desiccation and disinfection regimes as well as host immune responses such as serum complement. Additionally, capsule has been shown to confer resistance to a range of clinically relevant antimicrobial compounds. Distressingly, treatment options for A. baumannii infections are becoming increasingly limited, and the urgency to develop effective infection control strategies and therapies to combat infections is apparent. An increased understanding of the contribution of capsule to the pathobiology of A. baumannii is required to determine its feasibility as a target for new strategies to combat drug resistant infections. Significant variation in capsular polysaccharide structures between A. baumannii isolates has been identified, with over 100 distinct capsule types, incorporating a vast variety of sugars. This review examines the studies undertaken to elucidate capsule diversity and advance our understanding of the role of capsule in A. baumannii pathogenesis.
Introduction
Nosocomial infections caused by multidrug resistant Acinetobacter baumannii are becoming increasingly common worldwide, especially in the intensive care setting (Wieland et al., 2018). The success of this bacterium is facilitated by its ability to survive in a variety of environments compounded by its rapid ability to acquire multidrug resistance. Surface carbohydrates play key roles in the overall fitness and virulence of A. baumannii (; ; Weber et al., 2016). A. baumannii produces high molecular weight capsular polysaccharide (CPS) which surrounds the outer membrane (Figure 1) (Russo et al., 2010). Comprised of tightly packed repeating oligosaccharide subunits (K units), CPS forms a discrete layer on the bacterial surface providing protection from diverse environmental conditions, assisting in evasion of host immune defenses, and increasing resistance to a number of antimicrobial compounds (Russo et al., 2010; ; ).
FIGURE 1
In A. baumannii, capsule assembly and export occurs via a Wzy-dependent pathway (; ; Willis and Whitfield, 2013; Woodward and Naismith, 2016) (Figure 1). Typically consisting of 4–6 sugars, the K unit is assembled on the lipid carrier molecule undecaprenyl pyrophosphate (Und-P) which provides a scaffold for the growing sugar chain (Whitfield, 2006). The first sugar in the K unit is recruited by an inner membrane (IM)-bound initial transferase (Itr), followed by the sequential addition of sugars to the growing K unit by specific glycosyl transferase (Gtr) enzymes (Figure 1) (Woodward and Naismith, 2016). Each K unit is then transferred to the periplasmic side of the IM by the Wzx translocase and polymerized by Wzy, which transfers the growing polysaccharide chain from one Und-P carrier to the next incoming subunit (Figure 1) (). After the CPS polymer is synthesized, it is transported to the cell surface via a highly co-ordinated process involving the interaction of three proteins; Wza, Wzb, and Wzc, that comprise the export machinery (Figure 1). CPS synthesis represents one arm of a bifurcated pathway, as these K units are also used to decorate certain surface proteins via O-linked protein glycosylation (). In this case, single K units are transferred to recipient proteins by the O-oligosaccharyltransferase PglL (Figure 1) (). In A. baumannii, protein glycosylation contributes to biofilm formation by enhancing initial attachment and maturation of biofilms, and pathogenicity as demonstrated in a number of animal infection models (; Scott et al., 2014; ). Biofilm is a growth state in which bacterial communities are enclosed within an exopolysaccharide matrix and has been shown to play a significant role in A. baumannii persistence and resistance.
Other surface carbohydrates known to influence pathogenicity of A. baumannii include lipooligosaccharide (LOS) and the exopolysaccharide poly-β-(1-6)-N-acetylglucosamine (PNAG) (; Weber et al., 2016). PNAG forms the cohesive “glue” of biofilms and constitutes a substantial proportion of biofilms (; ). Unlike most Gram-negative bacteria, A. baumannii does not produce traditional lipopolysaccharide, but instead a similar surface glyco-conjugate, LOS, comprised of a lipid A core that lacks O-antigen (; ). Loss of LOS production in A. baumannii decreases stability of the outer membrane leading to reduced fitness (; ).
Although many carbohydrate moieties influence pathogenicity, it can be argued that CPS is a predominant virulence factor of A. baumannii. This review aims to consolidate what is known about A. baumannii capsule including selected structures, biosynthesis and gene organization, the role of CPS in virulence, and the potential for CPS as a target for future vaccine and drug development.
Genetic Organization of K Loci
As the complete genomes of more A. baumannii isolates become available, the true diversity of capsule structures present within this bacterium is becoming apparent. To date, over 100 unique capsule loci (KL) have been identified in A. baumannii (Figure 2A) (Shashkov et al., 2017). These regions typically range from 20 to 35 kb in size. Analysis of the genes directing CPS synthesis in ten complete A. baumannii genomes originally resulted in the designation of nine capsule types, KL1–KL9, which became the basis for a universal typing scheme for these loci (). This scheme has subsequently expanded to accommodate the identification of new K loci. The chromosomal location of the K locus, between the fkpA and lldP genes, is highly conserved between A. baumannii strains and contains those genes required for the biosynthesis and export specific to each CPS type (Figure 2) (; ). An exception to this rule are A. baumannii strains possessing KL19 and KL39 regions, where the gene encoding the Wzy polymerase, wzy, is found on a small genetic island elsewhere on the chromosome (). Additionally, the genes required for some of the common sugars seen in CPS are found elsewhere. All K loci show a similar genetic configuration, a highly variable cluster of synthesis and transferase genes required for the biosynthesis of unique KL-type complex sugars, flanked on one side by the highly conserved CPS export genes, and on the other side by a set of genes encoding conserved simple sugars and precursors (Figure 2A). The wzx and wzy genes required for repeat-unit processing are highly variable between K loci (Figure 2A, light blue), indicating specificity for particular K unit structures and, in general, the order of gtr determinants, encoding specific glycosyltransferases within the KL regions, inversely corresponds with the order of action.
FIGURE 2
The variable region of some KL gene clusters, such as KL37 and KL14, lack genes for complex sugar synthesis, as they only contain simple sugars in their K units (
CPS Structures
The earliest studies on CPS serotyping of A. baumannii were driven by the need to develop a method to discriminate A. baumannii isolates from other Acinetobacter species, as phenotypic analysis was burdened with ambiguity and misidentification (Traub, 1989). As described above, there is phenomenal diversity seen in A. baumannii CPS biosynthesis gene clusters, which translates into the diversity seen in K unit structure (
Variation between K unit structures may be subtle, for example, K12 and K13 differ only by the linkage of two glycans, which requires the use of an alternate Wzy polymerase; accordingly, the K loci of both strains are identical except for the wzy gene (Figure 2). Alternatively the variation may be striking, such as the incorporation of rare sugars including pseudaminic, legionaminic, or acinetaminic acid derivatives as seen in K2/6, K49, and K12/13 structures, respectively (Figure 2) (
Role in Virulence, Antimicrobial Resistance, and Persistence
It is beyond doubt that the presence of CPS is essential for A. baumannii pathogenicity. Not only is it necessary for evasion of host immune defenses (Russo et al., 2010;
Besides protection from host defenses, in A. baumannii CPS production increases resistance to a range of antimicrobial compounds, including those used for disinfection in clinical settings (
The ability of A. baumannii to persist in the clinical environment has undoubtedly enhanced colonization and infections in susceptible patients. A. baumannii is capable of surviving for months on hospital surfaces such as bed rails, furniture and medical devices, providing a reservoir that is often the source of transmission and infection (Wendt et al., 1997;
Recent studies have linked the phase-variable phenotype of A. baumannii AB5075 with alterations in CPS production, as highly virulent opaque variants produce a CPS layer with twice the thickness of their translucent counterparts (
Regulation of CPS Production
Environmental cues, such as temperature, osmotic pressure and changes in metabolite and ion availability can influence bacterial CPS production (
CPS as a Target for the Development of Vaccines and Treatments Against A. baumannii
Antibiotic (specifically cabapenem) resistant A. baumannii are classified a World Health Organization Priority 1 Critical organism for the development of new antimicrobials (WHO, 2017). Although there are no non-antibiotic treatments or vaccines licensed for A. baumannii at present, there is an increased interest in their development and preliminary studies look promising. Surface exposure and prevalence in pathogenic strains of A. baumannii makes CPS an ideal target for both antimicrobial treatments and vaccines (
Several studies have shown the efficacy of passive immunization in mice using a CPS-specific antibody, which is protective against bacterial challenge with 13–55% of clinical A. baumannii isolates (
Interest in phage therapy to treat bacterial infections has increased in recent years in response to the current crisis of rising antimicrobial resistance. Phage therapy is attractive as a potential treatment avenue for multidrug resistant A. baumannii infections. For example, a phage encoding a CPS depolymerase was found to degrade the CPS of approximately 10%, four out of 38, clinical multidrug resistant A. baumannii tested (
Concluding Remarks
Although capsule represents an important virulence trait of A. baumannii there are limited data available on the role different CPS types play in causing disease. To develop effective vaccines and therapies targeting CPS, we must first gain a comprehensive understanding towards the mechanisms behind its synthesis and expression, alongside the advantages that capsule conveys to the host bacteria. This research needs to be addressed in the context of the extreme variation of CPS serotypes found in A. baumannii, to ensure potential interventions work against strains producing diverse CPS structures. Further studies on CPS are required to provide a platform for the development of preventative measures and treatments against this increasingly persistent and deadly human pathogen.
Statements
Author contributions
JS wrote the first draft. MB provided academic input and critical revision of the article. FA produced genome alignments and provided critical revision of the manuscript. All authors approved the final version.
Funding
This work was supported by a Flinders Medical Research Foundation Grant to MB. FA was supported by AJ and IM Naylon and Playford Trust Ph.D. Scholarships. JS was supported by a AJ and IM Naylon Scholarship.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
ArbatskyN. P.ShneiderM. M.KenyonJ. J.ShashkovA. S.PopovaA. V.MiroshnikovK. A.et al (2015). Structure of the neutral capsular polysaccharide of Acinetobacter baumannii NIPH146 that carries the KL37 capsule gene cluster.Carbohydr. Res.41312–15. 10.1016/j.carres.2015.05.003
2
BeceiroA.MorenoA.FernándezN.VallejoJ. A.ArandaJ.AdlerB.et al (2014). Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii.Antimicrob. Agents Chemother.58518–526. 10.1128/AAC.01597-13
3
BravoZ.OrruñoM.ParadaC.KaberdinV.BarcinaI.AranaI. (2016). The long-term survival of Acinetobacter baumannii ATCC 19606T under nutrient-deprived conditions does not require the entry into the viable but non-culturable state.Arch. Microbiol.198399–407. 10.1007/s00203-016-1200-1
4
ChenX.MengX.GaoQ.ZhangG.GuH.GuoX. (2017). Meropenem selection induced overproduction of the intrinsic carbapenemase as well as phenotype divergence in Acinetobacter baumannii.Int. J. Antimicrob. Agents50419–426. 10.1016/j.ijantimicag.2017.04.015
5
ChiangS.-R.JungF.TangH.-J.ChenC.-H.ChenC.-C.ChouH.-Y.et al (2017). Desiccation and ethanol resistances of multidrug resistant Acinetobacter baumannii embedded in biofilm: the favorable antiseptic efficacy of combination chlorhexidine gluconate and ethanol.J. Microbiol. Immunol. Infect.51770–777. 10.1016/j.jmii.2017.02.003
6
ChinC. Y.TiptonK. A.FarokhyfarM.BurdE. M.WeissD. S.RatherP. N. (2018). A high-frequency phenotypic switch links bacterial virulence and environmental survival in Acinetobacter baumannii.Nat. Microbiol.3563–569. 10.1038/s41564-018-0151-5
7
ChoiA. H.SlamtiL.AvciF. Y.PierG. B.Maira-LitránT. (2009). The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-β-1-6-N-acetylglucosamine, which is critical for biofilm formation.J. Bacteriol.1915953–5963. 10.1128/JB.00647-09
8
CollinsR. F.BeisK.DongC.BottingC. H.McDonnellC.FordR. C.et al (2007). The 3D structure of a periplasm-spanning platform required for assembly of group 1 capsular polysaccharides in Escherichia coli.Proc. Natl. Acad. Sci. U.S.A.1042390–2395. 10.1073/pnas.0607763104
9
García-QuintanillaM.PulidoM. R.López-RojasR.PachónJ.McConnellM. J. (2013). Emerging therapies for multidrug resistant Acinetobacter baumannii.Trends Microbiol.21157–163. 10.1016/j.tim.2012.12.002
10
GayosoC. M.MateosJ. S.MeìndezJ. A.Fernaìndez-PuenteP.RumboC.TomaìsM.et al (2013). Molecular mechanisms involved in the response to desiccation stress and persistence in Acinetobacter baumannii.J. Proteome Res.13460–476. 10.1021/pr400603f
11
GeisingerE.IsbergR. R. (2015). Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii.PLoS Pathog.11:e1004691. 10.1371/journal.ppat.1004691
12
GeisingerE.MortmanN. J.Vargas-CuebasG.TaiA. K.IsbergR. R. (2018). A global regulatory system links virulence and antibiotic resistance to envelope homeostasis in Acinetobacter baumannii.PLoS Pathog.14:e1007030. 10.1371/journal.ppat.1007030
13
HagiwaraD.SugiuraM.OshimaT.MoriH.AibaH.YamashinoT.et al (2003). Genome-wide analyses revealing a signaling network of the RcsC-YojN-RcsB phosphorelay system in Escherichia coli.J. Bacteriol.1855735–5746. 10.1128/JB.185.19.5735-5746.2003
14
HardingC. M.NasrM. A.KinsellaR. L.ScottN. E.FosterL. J.WeberB. S.et al (2015). Acinetobacter strains carry two functional oligosaccharyltransferases, one devoted exclusively to type IV pilin, and the other one dedicated to O-glycosylation of multiple proteins.Mol. Microbiol.961023–1041. 10.1111/mmi.12986
15
Hernandez-MoralesA.LessorL.WoodT.MiglD.MijalisE.CahillJ.et al (2018). Genomic and biochemical characterization of Acinetobacter podophage petty reveals a novel lysis mechanism and tail-associated depolymerase activity.J. Virol.92:e01064-17. 10.1128/JVI.01064-17.
16
HitchenP.BrzostekJ.PanicoM.ButlerJ. A.MorrisH. R.DellA.et al (2010). Modification of the Campylobacter jejuni flagellin glycan by the product of the Cj1295 homopolymeric-tract-containing gene.Microbiology1561953–1962. 10.1099/mic.0.038091-0
17
HuD.LiuB.DijkshoornL.WangL.ReevesP. R. (2013). Diversity in the major polysaccharide antigen of Acinetobacter baumannii assessed by DNA sequencing, and development of a molecular serotyping scheme.PLoS One8:e70329. 10.1371/journal.pone.0070329
18
HuangT.-W.LamI.ChangH.-Y.TsaiS.-F.PalssonB. O.CharusantiP. (2014). Capsule deletion via a lamda-Red knockout system perturbs biofilm formation and fimbriae expression in Klebsiella pneumoniae MGH 78578.BMC Res. Notes7:13. 10.1186/1756-0500-7-13
19
IwashkiwJ. A.SeperA.WeberB. S.ScottN. E.VinogradovE.StratiloC.et al (2012). Identification of a general O-linked protein glycosylation system in Acinetobacter baumannii and its role in virulence and biofilm formation.PLoS Pathog.8:e1002758. 10.1371/journal.ppat.1002758
20
KaoC.-Y.SheuB.-S.WuJ.-J. (2016). Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis.Biomed. J.3914–23. 10.1016/j.bj.2015.06.002
21
KasimovaA.ShneiderM.ArbatskyN.PopovaA.ShashkovA.MiroshnikovK.et al (2017). Structure and gene cluster of the K93 capsular polysaccharide of Acinetobacter baumannii B11911 containing 5-N-Acetyl-7-N-[(R)-3-hydroxybutanoyl] pseudaminic acid.Biochemistry4483–489.
22
KasimovaA. A.KenyonJ. J.ArbatskyN. P.ShashkovA. S.PopovaA. V.ShneiderM. M.et al (2018). Acinetobacter baumannii K20 and K21 capsular polysaccharide structures establish roles for UDP-glucose dehydrogenase Ugd2, pyruvyl transferase Ptr2 and two glycosyltransferases.Glycobiology28876–884. 10.1093/glycob/cwy074
23
KenyonJ. J.HallR. M. (2013). Variation in the complex carbohydrate biosynthesis loci of Acinetobacter baumannii genomes.PLoS One8:e62160. 10.1371/journal.pone.0062160
24
KenyonJ. J.HallR. M.De CastroC. (2015). Structural determination of the K14 capsular polysaccharide from an ST25 Acinetobacter baumannii isolate, D46.Carbohydr. Res.41752–56. 10.1016/j.carres.2015.09.002
25
KenyonJ. J.MarzaioliA.HallR. M.De CastroC. (2014a). Structure of the K2 capsule associated with the KL2 gene cluster of Acinetobacter baumannii.Glycobiology24554–563. 10.1093/glycob/cwu024
26
KenyonJ. J.NigroS. J.HallR. M. (2014b). Variation in the OC Locus of Acinetobacter baumannii genomes predicts extensive structural diversity in the lipooligosaccharide.PLoS One9:e107833. 10.1371/journal.pone.0107833
27
KenyonJ. J.NotaroA.HsuL. Y.De CastroC.HallR. M. (2017). 5, 7-Di-N-acetyl-8-epiacinetaminic acid: a new non-2-ulosonic acid found in the K73 capsule produced by an Acinetobacter baumannii isolate from Singapore.Sci. Rep.7:11357. 10.1038/s41598-017-11166-4
28
KenyonJ. J.ShneiderM. M.SenchenkovaS. N.ShashkovA. S.SiniaginaM. N.MalaninS. Y.et al (2016a). K19 capsular polysaccharide of Acinetobacter baumannii is produced via a Wzy polymerase encoded in a small genomic island rather than the KL19 capsule gene cluster.Microbiology1621479–1489. 10.1099/mic.0.000313
29
KenyonJ. J.SpecialeI.HallR. M.De CastroC. (2016b). Structure of repeating unit of the capsular polysaccharide from Acinetobacter baumannii D78 and assignment of the K4 gene cluster.Carbohydr. Res.43412–17. 10.1016/j.carres.2016.07.016
30
LaiY.-C.PengH.-L.ChangH.-Y. (2003). RmpA2, an activator of capsule biosynthesis in Klebsiella pneumoniae CG43, regulates K2 cps gene expression at the transcriptional level.J. Bacteriol.185788–800. 10.1128/JB.185.3.788-800.2003
31
LeeI.-M.YangF.-L.ChenT.-L.LiaoK.-S.RenC.-T.LinN.-T.et al (2018). Pseudaminic acid on exopolysaccharide of Acinetobacter baumannii plays a critical role in phage-assisted preparation of glycoconjugate vaccine with high antigenicity.J. Am. Chem. Soc.1408639–8643. 10.1021/jacs.8b04078
32
Lees-MillerR. G.IwashkiwJ. A.ScottN. E.SeperA.VinogradovE.SchildS.et al (2013). A common pathway for O-linked protein-glycosylation and synthesis of capsule in Acinetobacter baumannii.Mol. Microbiol.89816–830. 10.1111/mmi.12300
33
LongoF.VuottoC.DonelliG. (2014). Biofilm formation in Acinetobacter baumannii.New Microbiol.37119–127.
34
LukeN. R.SauberanS. L.RussoT. A.BeananJ. M.OlsonR.LoehfelmT. W.et al (2010). Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis.Infect. Immun.782017–2023. 10.1128/IAI.00016-10
35
McQuearyC. N.KirkupB. C.SiY.BarlowM.ActisL. A.CraftD. W.et al (2012). Extracellular stress and lipopolysaccharide modulate Acinetobacter baumannii surface-associated motility.J. Microbiol.50434–443. 10.1007/s12275-012-1555-1
36
MerabishviliM.MonserezR.van BelleghemJ.RoseT.JennesS.De VosD.et al (2017). Stability of bacteriophages in burn wound care products.PLoS One12:e0182121. 10.1371/journal.pone.0182121
37
MoffattJ. H.HarperM.HarrisonP.HaleJ. D.VinogradovE.SeemannT.et al (2010). Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.Antimicrob. Agents Chemother.544971–4977. 10.1128/AAC.00834-10
38
MouslimC.DelgadoM.GroismanE. A. (2004). Activation of the RcsC/YojN/RcsB phosphorelay system attenuates Salmonella virulence.Mol. Microbiol.54386–395. 10.1111/j.1365-2958.2004.04293.x
39
OphirT.GutnickD. L. (1994). A role for exopolysaccharides in the protection of microorganisms from desiccation.Appl. Environ. Microbiol.60740–745.
40
PrestonA.MandrellR. E.GibsonB. W.ApicellaM. A. (1996). The lipooligosaccharides of pathogenic Gram-negative bacteria.Crit. Rev. Microbiol.22139–180. 10.3109/10408419609106458
41
RobersonE. B.FirestoneM. K. (1992). Relationship between desiccation and exopolysaccharide production in a soil Pseudomonas sp.Appl. Environ. Microbiol.581284–1291.
42
RobertsI. S. (1996). The biochemistry and genetics of capsular polysaccharide production in bacteria.Annu. Rev. Microbiol.50285–315. 10.1146/annurev.micro.50.1.285
43
RussoT. A.BeananJ. M.OlsonR.MacDonaldU.CoxA. D.MichaelF. S.et al (2013). The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.Infect. Immun.81915–922. 10.1128/IAI.01184-12
44
RussoT. A.LukeN. R.BeananJ. M.OlsonR.SauberanS. L.MacDonaldU.et al (2010). The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.Infect. Immun.783993–4000. 10.1128/IAI.00366-10
45
Sanchez-LarrayozA. F.ElhosseinyN. M.ChevretteM. G.FuY.GiuntaP.SpallanzaniR. G.et al (2017). Complexity of complement resistance factors expressed by Acinetobacter baumannii needed for survival in human serum.J. Immunol.1992354–2368. 10.4049/jimmunol.1700877
46
ScottN. E.KinsellaR. L.EdwardsA. V.LarsenM. R.DuttaS. M.SabaJ.et al (2014). Diversity within the O-linked protein glycosylation systems of Acinetobacter species.Mol. Cell. Proteomics132354–2370. 10.1074/mcp.M114.038315
47
ShashkovA. S.KenyonJ. J.ArbatskyN. P.ShneiderM. M.PopovaA. V.KnirelY. A.et al (2018). Genetics of biosynthesis and structure of the K53 capsular polysaccharide of Acinetobacter baumannii D23 made up of a disaccharide K unit.Microbiology1641–4. 10.1099/mic.0.000710
48
ShashkovA. S.LiuB.KenyonJ. J.PopovaA. V.ShneiderM. M.Sof’yaN. S.et al (2017). Structures of the K35 and K15 capsular polysaccharides of Acinetobacter baumannii LUH5535 and LUH5554 containing amino and diamino uronic acids.Carbohydr. Res.44828–34. 10.1016/j.carres.2017.05.017
49
SullivanM. J.PettyN. K.BeatsonS. A. (2011). Easyfig: a genome comparison visualizer.Bioinformatics271009–1010. 10.1093/bioinformatics/btr039
50
TiptonK. A.ChinC.-Y.FarokhyfarM.WeissD. S.RatherP. N. (2018). Role of capsule in resistance to disinfectants, host antimicrobials and desiccation in Acinetobacter baumannii.Antimicrob. Agents Chemother.62:e01188-18. 10.1128/AAC.01188-18.
51
TiptonK. A.DimitrovaD.RatherP. N. (2015). Phase-variable control of multiple phenotypes in Acinetobacter baumannii strain AB5075.J. Bacteriol.1972593–2599. 10.1128/JB.00188-15
52
TiptonK. A.RatherP. N. (2017). An ompR-envZ two-component system ortholog regulates phase variation, osmotic tolerance, motility, and virulence in Acinetobacter baumannii strain AB5075.J. Bacteriol.199:e00705-16. 10.1128/JB.00705-16
53
TraubW. H. (1989). Acinetobacter baumannii serotyping for delineation of outbreaks of nosocomial cross-infection.J. Clin. Microbiol.272713–2716.
54
UmlandT. C.SchultzL. W.MacDonaldU.BeananJ. M.OlsonR.RussoT. A. (2012). In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media.mBio3:e00113-12. 10.1128/mBio.00113-12
55
VinogradovE.MacLeanL.XuH. H.ChenW. (2014). The structure of the polysaccharide isolated from Acinetobacter baumannii strain LAC-4.Carbohydr. Res.39042–45. 10.1016/j.carres.2014.03.001
56
Wang-LinS. X.OlsonR.BeananJ. M.MacDonaldU.BalthasarJ. P.RussoT. A. (2017). The capsular polysaccharide of Acinetobacter baumannii is an obstacle for therapeutic passive immunization strategies.Infect. Immun.85:e00591-17. 10.1128/IAI.00591-17
57
WeberB. S.HardingC. M.FeldmanM. F. (2016). Pathogenic Acinetobacter: from the cell surface to infinity and beyond.J. Bacteriol.198880–887. 10.1128/JB.00906-15
58
WebsterC.TownerK. J.HumphreysH. (2000). Survival of Acinetobacter on three clinically related inanimate surfaces.Infect. Control Hosp. Epidemiol.21246–246. 10.1086/503214
59
WendtC.DietzeB.DietzE.RüdenH. (1997). Survival of Acinetobacter baumannii on dry surfaces.J. Clin. Microbiol.351394–1397.
60
WhitfieldC. (2006). Biosynthesis and assembly of capsular polysaccharides in Escherichia coli.Annu. Rev. Biochem.7539–68. 10.1146/annurev.biochem.75.103004.142545
61
WhitfieldC.PaimentA. (2003). Biosynthesis and assembly of Group 1 capsular polysaccharides in Escherichia coli and related extracellular polysaccharides in other bacteria.Carbohydr. Res.3382491–2502. 10.1016/j.carres.2003.08.010
62
WHO (2017). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics.Geneva: World Health Organisation.
63
WielandK.ChhatwalP.VonbergR.-P. (2018). Nosocomial outbreaks caused by Acinetobacter baumannii and Pseudomonas aeruginosa: results of a systematic review.Am. J. Infect. Control46643–648. 10.1016/j.ajic.2017.12.014
64
WillenborgJ.FuldeM.de GreeffA.RohdeM.SmithH. E.Valentin-WeigandP.et al (2011). Role of glucose and CcpA in capsule expression and virulence of Streptococcus suis.Microbiology1571823–1833. 10.1099/mic.0.046417-0
65
WillisL. M.WhitfieldC. (2013). “Chapter 17 - Capsule and lipopolysaccharide,” inEscherichia coli, 2nd Edn, ed.DonnenbergM. S. (Boston, MA: Academic Press), 533–556. 10.1016/B978-0-12-397048-0.00017-6
66
WoodwardL.NaismithJ. H. (2016). Bacterial polysaccharide synthesis and export.Curr. Opin. Struct. Biol.4081–88. 10.1016/j.sbi.2016.07.016
67
WuM.-F.YangC.-Y.LinT.-L.WangJ.-T.YangF.-L.WuS.-H.et al (2009). Humoral immunity against capsule polysaccharide protects the host from magA++ Klebsiella pneumoniae-induced lethal disease by evading Toll-like receptor 4 signaling.Infect. Immun.77615–621. 10.1128/IAI.00931-08
68
YangF.-L.LouT.-C.KuoS.-C.WuW.-L.ChernJ.LeeY.-T.et al (2017). A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate.Vaccine351440–1447. 10.1016/j.vaccine.2017.01.060
Summary
Keywords
Acinetobacter, capsule, polysaccharide, virulence factor, persistence
Citation
Singh JK, Adams FG and Brown MH (2019) Diversity and Function of Capsular Polysaccharide in Acinetobacter baumannii. Front. Microbiol. 9:3301. doi: 10.3389/fmicb.2018.03301
Received
08 October 2018
Accepted
18 December 2018
Published
09 January 2019
Volume
9 - 2018
Edited by
Maria Alejandra Mussi, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
Reviewed by
Filipa Grosso, Universidade do Porto, Portugal; Ayush Kumar, University of Manitoba, Canada
Updates

Check for updates
Copyright
© 2019 Singh, Adams and Brown.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Melissa H. Brown, melissa.brown@flinders.edu.au
This article was submitted to Infectious Diseases, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.